ArticleFrontiers in immunology2025

Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma.

Lingling Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.